Leite Elaine Amaral, Giuberti Cristiane dos Santos, Wainstein Alberto J A, Wainstein Ana Paula D L, Coelho Luiz G V, Lana Angela M Q, Savassi-Rocha Paulo R, De Oliveira Mônica Cristina
Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, Minas Gerais, Brazil.
Life Sci. 2009 May 8;84(19-20):641-9. doi: 10.1016/j.lfs.2009.02.002. Epub 2009 Feb 11.
The objective of this work was to evaluate the acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin (SpHL-CDDP), after their intraperitoneal administration in male and female mice.
After single administration of free CDDP (5,10,and 20 mg/kg) or SpHL-CDDP (7,12,30,45 and 80 mg/kg), the body weight was recorded and the LD(50) was calculated. Blood samples were collected for biochemical and hematological analysis. Kidneys, liver, spleen and bone marrow were removed to histopathological examination.
Mice treated with high doses of free CDDP showed a greater loss of body weight and more delayed recovery time than those treated with SpHL-CDDP. The LD(50) values for SpHL-CDDP treatment for male and female mice groups were 2.7 and 3.2 fold higher, respectively, than that obtained for free CDDP. The red and white blood cells counts and quantification of hemoglobin and hematocrit presented no change upon administration of SpHL-CDDP treatment. Free CDDP treatment, however, did lead to an appearance of mild anemia and a reduction in total white blood cell counts. As regards nephrotoxicity, it was observed that free CDDP treatment caused pronounced alterations in the blood urea and creatinine levels of mice. In contrast, these parameters were slightly altered only after SpHL-CDDP treatment at a dose of 30 mg/kg. Microscopic analysis of kidneys from mice treated with SpHL-CDDP showed no morphological alteration. Concerning hepatotoxicity, no histopathological alteration was observed after both treatments.
These findings reveal that SpHL-CDDP can eliminate CDDP-induced toxicity and is thus a promising candidate for intraperitoneal chemotherapy.
本研究旨在评估顺铂长循环pH敏感脂质体(SpHL-CDDP)腹腔注射给药后对雄性和雌性小鼠的急性毒性。
单次给予游离顺铂(5、10和20mg/kg)或SpHL-CDDP(7、12、30、45和80mg/kg)后,记录体重并计算半数致死量(LD50)。采集血样进行生化和血液学分析。取出肾脏、肝脏、脾脏和骨髓进行组织病理学检查。
高剂量游离顺铂治疗的小鼠比SpHL-CDDP治疗的小鼠体重减轻更明显,恢复时间更延迟。SpHL-CDDP治疗的雄性和雌性小鼠组的LD50值分别比游离顺铂高2.7倍和3.2倍。给予SpHL-CDDP治疗后,红细胞和白细胞计数以及血红蛋白和血细胞比容的定量均无变化。然而,游离顺铂治疗确实导致轻度贫血的出现和总白细胞计数的减少。关于肾毒性,观察到游离顺铂治疗导致小鼠血尿素和肌酐水平发生明显变化。相比之下,仅在30mg/kg剂量的SpHL-CDDP治疗后,这些参数略有改变。对SpHL-CDDP治疗的小鼠肾脏进行显微镜分析,未发现形态学改变。关于肝毒性,两种治疗后均未观察到组织病理学改变。
这些发现表明,SpHL-CDDP可以消除顺铂诱导的毒性,因此是腹腔化疗的一个有前景的候选药物。